NanoCell Therapeutics, Inc. has published research in the Journal for ImmunoTherapy of Cancer detailing its NCtx platform's ability to generate CAR-T cells directly within the body. This approach uses targeted lipid nanoparticles to deliver DNA to T cells, enabling durable CAR expression and anti-tumor activity with a single injection. The study addresses a critical bottleneck in CAR-T therapy: the high cost and complexity of ex vivo manufacturing.
Current CAR-T therapies, while effective against certain blood cancers, require a complex process of extracting a patient's T cells, genetically engineering them in a specialized facility, and reinfusing them. This process costs approximately $300,000 per patient and involves lengthy production times. NanoCell's NCtx platform co-delivers minicircle DNA and transposase mRNA within a single nanoparticle, simplifying the manufacturing process and potentially making CAR-T therapies more accessible.
In humanized mouse models, the NCtx platform demonstrated significant tumor control and extended survival at low doses. Dr. Jacek Lubelski, Chief Technology Officer at NanoCell, stated that the platform could simplify treatment protocols and expand access globally. The company has collaborated with Shanghai Cell Therapy Group (SHCell) to combine NanoCell's delivery technology with SHCell's innovative CAR designs. The modularity of the platform allows for adaptation across various therapeutic targets, suggesting a broad impact beyond B cell cancers.
This research was supported by the European Union's Horizon Europe and Horizon 2020 programs. NanoCell is preparing for an Investigational Medicinal Product Dossier (IMPD) application pending financing, marking a critical step toward clinical development. The NCtx platform represents a promising advancement in gene therapy, potentially transforming treatment accessibility for cancer patients worldwide.
